Skip to main content

Search
Infectious Disease

Research Funding

|

Research Funding

Grant TitleGrantorAmountAward Date
Lakshmi Rajagopal, PhDRole of an ornithine rhamnolipid pigment in GBS virulence - R01 AI112619NIH/NIAID $250,000 annual direct costsJuly 1, 2014 - June 30, 2019
Lisa M. Frenkel, MD"A rapid point-of-treatment diagnostic assay for HIV-resistance to 1st-line ART" - R01 AI110375NIH $250,000 annual direct costsMay 1, 2014 - April 30, 2019
Lisa M. Frenkel, MD"Evaluation of mHealth strategies to optimize adherence and efficacy of PMTCT/ART" - R01 HD080460 (PI: John-Stewart)NIH $11,393 subcontract annual direct costsMay 1, 2014 - April 30, 2019
Lisa M. Frenkel, MDMechanisms of Formation and Persistence of Active HIV Reservoirs - R01 AI111806 (PI: Mullins)NIH $114,390 subcontract annual direct costsApril 1, 2014 - March 31, 2019
Jane L. Burns, MDPrevalence and Clinical Significance of S. aureus small-colony variants - HOFFMA14A0 (PI: Burns and Hoffman)Cystic Fibrosis Foundation Therapeutics $109,481 Burns annual direct costsApril 1, 2014 - March 31, 2017
Timothy Rose, PhDPoint-of-care diagnosis and surveillance of known and emerging influenza viruses - R01 AI111303NIH/NIAID $855,731 annual directsMarch 15, 2014 - Feb. 28, 2019
Thor A. Wagner, MD"Mechanisms of Formation and Persistence of Active HIV Reservoirs" - R01 AI111806 (PI: Mullins)NIH $10,720 subcontract annual direct costsMarch 15, 2014 - Feb. 28, 2019
Lisa M. Frenkel, MD"International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group" Virology Lab - UM1 AI106716 (PI: Aldrovandi)NIH $95,547 annual direct costsJan. 1, 2014 - Nov. 30, 2020
Jane L. Burns, MDLong Term Outcomes after Eradication of Pseudomonas aeruginosa among Children Enrolled in the EPIC Clinical Trial - #CTBM100CUSNC01T (PI: Hamblett)Novartis $34,426 annual direct costsDec. 15, 2013 - Dec. 15, 2015
Lakshmi Rajagopal, PhDEnvironmental signals that regulate GBS virulence - R21 AI109222NIH/NIAID $150,000 annual direct costsSept. 1, 2013 - Aug. 31, 2015
Jane L. Burns, MDProof of Principle Evaluation of IV Gallium Nitrate in Patients with Cystic Fibrosis - UM1 HL119073 (PI: Goss) $, $55,495 Burns' annual direct costsSept. 1, 2013 - June 30, 2016
Lakshmi Rajagopal, PhDEukaryotic-type signaling mediates two-component regulation of GBS virulence - R56 AI070749-06A1NIH/NIAID $247,362 annual direct costsJune 11, 2013 - Dec. 31, 2014
Lisa M. Frenkel, MD"University of Washington Center for AIDS Research" (CFAR) - P30 AI027757 (PI: Holmes)NIH $95,547 annual direct costsJune 1, 2013 - May 31, 2015
Marta Bull, PhD"University of Washington Center for AIDS Research" (CFAR) - P30 AI027757 (PI: King Holmes)NIH $11,528 subcontract annual direct costsJune 1, 2013 - May 31, 2015
Janet A. Englund, MDClinical Significance of rhinovirusSeattle Children's Hospital Clinical Translational Research CenterDec. 20, 2012 - Sept. 30, 2013
Danielle M. Zerr, MD, MPHFrequency and Duration of Intestinal Carriage and Bacterial Evolution Over Time in Pediatric Patients with Resistant Enterobacteriaceae InfectionsChildren's Research Institute/Translational Research Ignition Projects Program $$50,000Dec. 12, 2012 - Sept. 30, 2013
Jane L. Burns, MDA Phase 2, Randomized, Double Blind, Placebo-Controlled, Repeat-Dose Study of KB001 A in Subjects with Cystic Fibrosis Infected with Pseudomonas aeruginosaKaloBios Pharmaceuticals, Inc. $45,032 total direct costsOct. 10, 2012 - Oct. 9, 2014
Danielle M. Zerr, MD, MPHImpact of chlorhexidine bathing on reducing infections in children with cancerNIH/NCI $$410,000Aug. 1, 2012
Lakshmi Rajagopal, PhDGBS mediated in utero fetal injury - R01 AI100989 (Co-PI with Kristina Adams Waldorf)NIH/NIAID $499,906 annual direct costsJuly 1, 2012 - June 30, 2017
Lisa M. Frenkel, MD"Drug-resistance testing in Kenya to improve ART suppression of HIV replication" (PEPFAR) - R01 AI100037NIH $695,729 annual direct costsJune 3, 2012 - May 31, 2015
Janet A. Englund, MDRSV surveillance and antibody levels in Southeast Asia PATHMay 2012 - June 2014
Lisa M. Frenkel, MD"Academic Pediatric Infectious Disease" - T32 HD007233NIH $277,930 annual direct costsMay 1, 2012 - April 30, 2017
Jane L. Burns, MDLab Services - Grifols Protocol# T6005-201Grifols Therapeutics, Inc.April 10, 2012 - April 10, 2014
Scott J. Weissman, MDDifferences in infecting and colonizing Enterobacteriaceae from short-course vs standard therapy of pediatric UTI - R21AI099930NIH/NIAID $125,000 annual DCApril 1, 2012 - Feb. 28, 2015
Jane L. Burns, MDPersistent MRSA Eradication Protocol - #PMEP11K1 (PI: Dasenbrook)CFFT $37,240 subcontract annual direct costsJan. 1, 2012 - Dec. 31, 2014
Thor A. Wagner, MDSystematic High-Throughput Screening of B-cell Repertoires to Identify Antibodies Specific for HIV-Infected CellsBill and Melinda Gates Foundation $, $Nov. 1, 2011 - April 30, 2013
Janet A. Englund, MDNew Vaccine Surveillance NetworkCDCAug. 1, 2011 - July 31, 2015
Timothy Rose, PhDOral pathogenesis and host interactions of KSHV infection - P01 DE021954NIH/NIDCR $993,231 + $120,000 annual directsJune 7, 2011 - April 30, 2016
Serge Barcy, PhDOral pathogenesis and host interactions of KSHV infection - P01 DE021954 (Rose)NIH/NIDCR $993,231 annual directsJune 1, 2011 - April 30, 2016
Lisa M. Frenkel, MD"HIV-1 evolution in the female genital tract and trafficking in the blood" - R01AI091550.NIH/NIAID $254,817 annual direct costsJan. 21, 2011 - Dec. 31, 2015
Marta Bull, PhD"HIV-1 evolution in the female genital tract and trafficking in the blood" - R01 AI091550 (PI: Frenkel)NIH $254,817 annual direct costsJan. 21, 2011 - Dec. 31, 2015
Lisa M. Frenkel, MD"Immunologic and Virologic Events in Early HIV Infection" (SEAPIP) - P01 AI057005 (Mullins).NIH $101,000 annual direct costsJuly 15, 2010 - June 30, 2015
Jane L. Burns, MDTranslational Research Center to Expedite Novel Therapies in Cystic Fibrosis - P30 DK089507 (PI: Ramsey & Greenberg)NIH $25,749 Burns' annual direct costsJuly 6, 2010 - May 31, 2015
Danielle M. Zerr, MD, MPHNational surveillance of emerging MDR in pediatric Enterobacteriaceae infectionsNIH/NIAID $437,668July 1, 2010
Scott J. Weissman, MDResistance and relatedness: Molecular features of Klebsiella pneumoniae as a colonizer and pathogen in pediatric patients in Seattle, WAInstitute of Translational Health Sciences/UWJune 3, 2010 - April 30, 2012
Scott J. Weissman, MDNational surveillance of emerging MDR in pediatric Enterobacteriaceae infections - R01 AI083413 (Co-PI with Zerr)NIH/NIAID $420,236 annual DCJune 1, 2010 - May 31, 2015
Jane Burns, MDSafety and efficacy of aztreonamGilead SciencesJan. 12, 2010 - Jan. 12, 2015
Thor A. Wagner, MDHIV Persistence Despite Therapy due to Proliferation of Infected CellsFraternal Order of EaglesOct. 1, 2009 - Sept. 30, 2014
Jane Burns, MDPseudomonas aeruginosa adaptation during early cystic fibrosis infection and treatmentNIH $, $Sept. 11, 2009 - July 31, 2014
Danielle Zerr, MD, MPHHHV-6 and CNS disease following stem cell transplantNIH/NIAID $278,321.00Sept. 1, 2009
Danielle Zerr, MD, MPHImpact of Daily Bathing with Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care UnitSage Products, Inc. $100,000.00Sept. 1, 2009
Danielle Zerr, MD, MPHNational surveillance of emerging MDR in pediatric Enterobacteriaceae infectionsNIH/NIAID $378,005.00Aug. 11, 2009
Timothy Rose, PhDPOC molecular method for detection of known and emerging respiratory virusesNIH/NIDCR $300,885.00July 1, 2009
Danielle Zerr, MD, MPHInfection Control of Keyboards (ICK) Study: A Randomized, Blinded, Multi-Center Study of Ultraviolet Light DecontaminationVioguard LLC $114,000.00June 1, 2009
Janet A. Englund, MDOperation of a Facility for the Study of Infectious Agents, Vaccines, and AntimicrobialsNIH/ Subsite of Johns HopkinsApril 7, 2009 - April 6, 2013
Lisa M. Frenkel, MD"Low-frequency HIV-1 Drug Resistance Mutations in Primary HIV-1 Infection" - R01 AI078802 (Steckler)NIH $61,594 annual direct costsApril 1, 2009 - June 30, 2015
Janet A. Englund, MDMaternal Immunization to protect the Mother and NeonateBill and Melinda Gates FndnJan. 2009 - Dec. 2014
Thor Wagner, MDNovel microcapillary immunoassay methodology to enable point-of-care infant HIV-1 diagnosisSeattle Children’s HospitalJan. 1, 2009
Danielle Zerr, MD, MPHEmerging MDR in pediatric Enterobacteriaceae infectionsCCTR Pediatric Pilot Award $20,000.00Dec. 1, 2008
Thor Wagner, MDPersistent HIV-1 Replication in the Respiratory Tract Despite Antiretroviral TreatmentNIH-NIAIDSept. 1, 2008 - Nov. 30, 2013
Thor A. Wagner, MDImproving Pediatric HIV-1 Diagnostics in an Effort to Avoid Antiretroviral Treatment Failure in Tamilnadu, IndiaBurroughs Wellcome Fund/American Society of Tropical Medicine and HygieneJuly 1, 2008 - June 30, 2014
Ann Melvin, MDBone mineral density in tenofovir-exposed infants and young childrenGilead Sciences Phase4 program $47,943.00June 23, 2008
Ann Melvin, MDBioethics coreNIH Cooperative Agreement $1,583,701.00June 1, 2008
Scott J. Weissman, MDMulti-drug resistance and virulence patterns in canine and feline urinary E. coliAmerican College of Veterinary MedicineJan. 1, 2008 - March 31, 2011
Ann Melvin, MDInternational and Domestic Pediatric and Maternal HIV Studies Coordinating CenterNIH $659,107.00Dec. 16, 2007
Lisa M. Frenkel, MD"International and Domestic Pediatric and Maternal HIV Studies Coordinating Center" - NO1-DK-8-0001 (Melvin).NIH $11,360 annual direct costsDec. 16, 2007 - Nov. 30, 2014
Timothy Rose, PhDViral and cellular factors involved in KSHV entry in cells of the oral mucosaNIH/NIDCR $1,125,000.00Aug. 15, 2007
Timothy Rose, PhDHerpesvirus latency and reactivation in macaque models of human diseaseNIH/NCRR $1,680,995.00July 1, 2007
Lisa M. Frenkel, MD"Occurrence and Outcome of Dual HIV-1 Infection" - R37 AI047734 (Mullins)NIH $4,987 annual direct costsJuly 5, 2005 - March 31, 2015
Ann Melvin, MDReservoirs of Drug-Resistant HIV-1 – US-India Collaborative Research SupplementNIH $58,907.00March 1, 2005
Danielle Zerr, MD, MPHHHV-6 and CNS disease following stem cell transplantNIH/NIAID $1,250,000.00July 1, 2004
Jane L. Burns, MDTherapeutics Development Network Coordinating Center (CFFT Infrastructure 2014-2015) (PI: Ramsey)CFFT $11,443 Burns' annual direct costsApril 1, 2004 - March 31, 2015
Jane Burns, MDTranslational Therapeutics Development Center - #GIBSON09YO (PI: Gibson)Cystic Fibrosis Foundation Therapeutics $166,400 annual direct costsApril 1, 2004 - Dec. 31, 2014
Danielle Zerr, MD, MPHViral Pathogens and First Time Seizures in the Setting of IllnessPrivate Donation $60,000.00June 30, 2003
Jane L. Burns, MDTherapeutic Development Center Microbiology Core Laboratory - #BURNS03Y3Cystic Fibrosis Foundation Therapeutics $112,315 annual direct costsApril 1, 2003 - Dec. 31, 2014
Charles Smith, PhDShort Term Research Training in Pediatrics for Medical Studentsunknown $182,260.00May 1, 1993
Academic Annual Report